- Efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) in virologically suppressed women
- Burden of exposure to potential interactions between antiretroviral and non-antiretroviral medications in a population of HIV-positive patients aged 50 years or older
- Alirocumab vs usual lipid-lowering care as add?on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
- Effect of cumulative exposure to corticosteroid and DMARD on radiographic progression in rheumatoid arthritis: Results from the ESPOIR cohort
- Trifluridine/tipiracil (TAS-102) in refractory metastatic colorectal cancer: A multicenter register in the frame of the Italian compassionate use program
- Treosulfan, fludarabine, and low-dose total body irradiation for children and young adults with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation: Prospective phase II trial of the pediatric blood and marrow transplant consortium
- Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status
- Acid?suppressive drugs and risk of kidney disease: A systematic review and meta?analysis
- Survival outcomes for advanced kidney cancer patients in the era of targeted therapies
- Anemia in patients with acute coronary syndromes treated with prasugrel or ticagrelor: Insights from the RENAMI registry
- Iglarlixi: A new once-daily fixed-ratio combination of basal insulin glargine and lixisenatide for the management of type 2 diabetes
- Alcohol and opioid use in chronic pain: A cross-sectional examination of differences in functioning based on misuse status
- An early view of real-world patient response to sacubitril/valsartan: a retrospective study of patients with heart failure with reduced ejection fraction
- Evaluation of responsiveness to reduced-dose rituximab in corticotropin/ivig/rituximab combination immunotherapy for opsoclonus-myoclonus syndrome
- Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
Feed Sources
